CHICAGO — At 2 years, crinecerfont demonstrated favorable effects on weight, body composition and insulin resistance in adults with classic congenital adrenal hyperplasia, researchers reported at ENDO 2026.
In addition, crinecerfont (Crenessity, Neurocrine Biosciences) was associated with stable or improved bone age progression in children and adolescents with classic congenital adrenal hyperplasia (CAH), according to results from another ENDO 2026 presentation.
As Healio previously reported, crinecerfont was linked with substantial and sustained reductions in glucocorticoid doses and did not

CHICAGO — In postmenopausal women, use of menopausal hormone therapy was associated with higher bone mineral density compared with nonuse, according to a study presented at ENDO 2026.
“We undertook this study because menopausal hormone therapy (MHT) remains one of the most effective interventions for preserving bone mass after menopause, yet many eligible women continue to avoid treatment,” Diego Espinoza-Peralta, MD, MSc, endocrinologist at Investigación Médica Sonora in Hermosilla, Mexico, who presented the findings, told Healio. “We wanted to evaluate whether the association between MHT and

CHICAGO — Garetosmab reduced new heterotopic bone lesions in patients with fibrodysplasia ossificans progressiva at 56 weeks compared with placebo, according to results of the OPTIMA trial presented at ENDO 2026.
“[Fibrodysplasia ossificans progressiva] is an ultrarare disorder that affects about one in 1 million of the population,” Richard Keen, MD, PhD, director of the Centre for Metabolic Bone Disease, Royal National Orthopaedic Hospital NHS Trust in London, said during a presentation. “It’s caused by a dominant heterozygous gain-of-function mutation in ACVR1, which results in the formation